VAL-1221: Ph I/II started

Next month, Valerion will begin an open-label, international Phase I/II trial to evaluate 1, 3 and 10 mg IV VAL-1221 every 2 weeks for 12 weeks in up to 16 ambulatory and ventilator-free patients with...